Skip to main content
Clinical Trials/NCT06176859
NCT06176859
Active, not recruiting
Not Applicable

Delivery Optimization for Pre-Exposure Prophylaxis (DO PrEP) Study: A Prospective, Interventional, Randomized Study of Community-based PrEP Initiation, Delivery, and Monitoring in South Africa

Massachusetts General Hospital1 site in 1 country2,500 target enrollmentJuly 17, 2023

Overview

Phase
Not Applicable
Intervention
HIV PrEP Delivery
Conditions
HIV
Sponsor
Massachusetts General Hospital
Enrollment
2500
Locations
1
Primary Endpoint
The primary outcome is uptake of Pre-exposure prophylaxis of HIV (PrEP) .
Status
Active, not recruiting
Last Updated
3 months ago

Overview

Brief Summary

The overall goal is to determine whether an end-to-end decentralized delivery service for PrEP is more effective, safe, acceptable, and cost-effective than facility-based PrEP delivery.

Detailed Description

Optimizing pre-exposure prophylaxis (PrEP) delivery with a focus on priority populations is critical to realize the enormous potential of PrEP for HIV prevention. HIV incidence remains relentlessly high among young women and sexual minority men and primary prevention is critical to achieving control of the HIV epidemic. With effective and persistent use, oral pre-exposure prophylaxis (PrEP) for HIV prevents 75%-100% of HIV cases among cisgender women and men, gay and bisexual men, and transgender women. Despite the high efficacy, uptake throughout the PrEP prevention cascade remains low. South Africa is expanding PrEP provision but requires evidence-based strategies on how to achieve access, effective use, and persistence. The current clinic-based requirement of PrEP to persons at risk for HIV acquisition requires that clients self-identify their exposure to HIV and visit the clinic regularly for initiation, monitoring and refills. Barriers to PrEP access include clinic level factors (i.e. staff training, brief visits) and individual level factors including logistics such as transportation for clinic visits. The priority is to determine how to deliver PrEP in a scalable way and achieve high PrEP access and effective, persistent use. PrEP is a highly efficacious HIV prevention strategy but requires effective strategies that streamline delivery and engage users for scale-up. Community-based strategies for HIV testing, ART initiation, and monitoring successfully reach people living with HIV for treatment and have made marked improvements to viral suppression. This protocol describes a randomized clinical study to test an end-to-end decentralized delivery service for PrEP. It aims to safely increase PrEP access and use among priority populations in South Africa. Participants will include 16-30 year old HIV negative women and sexual minority men at high risk for acquiring HIV. As a critical component of decentralized delivery, we will also evaluate the safety and efficacy of HIV self-testing compared to rapid diagnostic tests.

Registry
clinicaltrials.gov
Start Date
July 17, 2023
End Date
May 1, 2026
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ruanne Barnabas, MBChB, MSc, DPhil.

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Aged 16 years - 30 years old,
  • Self-report living without HIV or unknown status.
  • Persons who have been sexually active within the last 3 months
  • Interested in the use of PrEP for HIV prevention.
  • Able and willing to provide informed consent for study procedures.
  • Access to a cellphone for study related communication
  • Reside in the study community for the duration of follow-up.

Exclusion Criteria

  • HIV infection based on negative HIV rapid tests
  • Clinically ineligible for PrEP
  • The participant doesn't reside in the study community for the duration of follow-up

Arms & Interventions

Home-based PrEP

In the home-based PrEP arm, participants will complete the HIV self-test at home with support received through telemedicine or over the phone. Confirmation of HIV test result will be shared with the provider through a photograph of the test. PrEP refills will be delivered to participants at home by courier.

Intervention: HIV PrEP Delivery

Community-based PrEP

In the community-based PrEP arm, participants will be tested using rapid diagnostic tests (RDT) in person (at a community venue) or through telemedicine (at a community venue) where they will be linked by counsellor telephonically to nurse or clinician. PrEP refills will be collected by participants at a community venue.

Intervention: HIV PrEP Delivery

Outcomes

Primary Outcomes

The primary outcome is uptake of Pre-exposure prophylaxis of HIV (PrEP) .

Time Frame: 36 Months

The proportion of study participants who effectively accessed PrEP and continued use over a 12-month period.

Secondary Outcomes

  • The efficacy of rapid HIV testing kits in diagnosing HIV for PrEP initiation.(36 Months)
  • Persistent use of PrEP over a 12-month period.(36 Months)
  • Cost effectiveness per HIV incident averted.(36 Months)

Study Sites (1)

Loading locations...

Similar Trials